Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

By K. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L. Demidov, J. Hassel, P. Rutkowski, P. Mohr and 9 more. 2012

1,221 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death (2017, background): “Combination therapy is a logical and clinically-proven path forward (Flaherty et al., 2012), but rationalizing even just the choice of combinations from among the at least 28 FDA-approved (Wu et al., 2015) targeted small molecule kinase inhibitors, notwithstanding important questions related to the…”
Overcoming Endocrine Resistance in Breast Cancer (2020, background): “Finally, inhibitors of the MAPK pathway (BRAF, MEK, and ERK inhibitors) may overcome endocrine resistance mediated by BRAF and MAP2K1 alterations (Flaherty et al., 2012; Lian et al., 2019; Sullivan et al., 2018).”
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. (2017, background): “Targeting of a node downstream of mutant BRAF (MEK1 or ERK2) was sufficient to induce vertical pathway lethality and in the case of MEK inhibition, this has been recapitulated clinically (Flaherty et al., 2012).”